{"generic":"Cytomegalovirus Immune Globulin, Human","drugs":["Cytogam","Cytomegalovirus Immune Globulin, Human"],"mono":{"0":{"id":"153000-s-0","title":"Generic Names","mono":"Cytomegalovirus Immune Globulin, Human"},"1":{"id":"153000-s-1","title":"Dosing and Indications","sub":{"0":{"id":"153000-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Cytomegalovirus infection; Prophylaxis - Transplantation of heart:<\/b> 150 mg\/kg IV within 72 hours of transplant and on weeks 2,4,6, and 8 post transplant and 100 mg\/kg on weeks 12 and 16 post transplant<\/li><li><b>Cytomegalovirus infection; Prophylaxis - Transplantation of liver:<\/b> 150 mg\/kg IV within 72 hours of transplant and on weeks 2,4,6, and 8 post transplant and 100 mg\/kg on weeks 12 and 16 post transplant<\/li><li><b>Cytomegalovirus infection; Prophylaxis - Transplantation of pancreas:<\/b> 150 mg\/kg IV within 72 hours of transplant and on weeks 2,4,6, and 8 post transplant and 100 mg\/kg on weeks 12 and 16 post transplant<\/li><li><b>Cytomegalovirus infection; Prophylaxis - Transplant of kidney:<\/b> 150 mg\/kg IV for 1 dose within 72 hours of transplant then 100 mg\/kg on weeks 2,4,6, and 8 post transplant and 50 mg\/kg on weeks 12 and 16 post transplant<\/li><li><b>Cytomegalovirus infection; Prophylaxis - Transplant of lung:<\/b> 150 mg\/kg IV within 72 hours of transplant and on weeks 2,4,6, and 8 post transplant and 100 mg\/kg on weeks 12 and 16 post transplant<\/li><\/ul>"},"1":{"id":"153000-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy in pediatrics have not been established"},"3":{"id":"153000-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cytomegalovirus infection; Prophylaxis - Transplantation of heart<\/li><li>Cytomegalovirus infection; Prophylaxis - Transplantation of liver<\/li><li>Cytomegalovirus infection; Prophylaxis - Transplantation of pancreas<\/li><li>Cytomegalovirus infection; Prophylaxis - Transplant of kidney<\/li><li>Cytomegalovirus infection; Prophylaxis - Transplant of lung<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Congenital cytomegalovirus infection; Treatment and Prophylaxis<br\/>"}}},"3":{"id":"153000-s-3","title":"Contraindications\/Warnings","sub":[{"id":"153000-s-3-9","title":"Contraindications","mono":"<ul><li>history of severe reactions to cytomegalovirus immune globulin or other human immunoglobulin preparations<\/li><li>immunoglobulin A deficiency, selective<\/li><\/ul>"},{"id":"153000-s-3-10","title":"Precautions","mono":"<ul><li>aseptic meningitis syndrome (AMS) has been reported with IV human immune globulin products; discontinue use if suspected<\/li><li>hemolytic anemia may occur with IV human immune globulin products; monitoring recommended<\/li><li>human plasma derivative; risk of transmitting infectious agent, including viruses and theoretical risk of Creutzfeldt-Jakob disease<\/li><li>predisposition to acute renal failure (eg, renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, concurrent treatment with nephrotoxic drugs); monitoring recommended; concentrations and infusion adjustments may be necessary<\/li><li>renal dysfunction, acute renal failure, osmotic nephrosis, and death have been reported with IV human immune globulin products; consider discontinuation if renal deterioration occurs<\/li><li>thrombotic events have been reported with IV human immune globulin products; monitoring recommended for patients at risk of hyperviscosity (eg, cryoglobulins, fasting chylomicronemia\/markedly high triacylglycerols, or monoclonal gammopathies)<\/li><li>transfusion-related acute lung injury (TRALI) has been reported with IV human immune globulin products; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"153000-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"153000-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"153000-s-4","title":"Drug Interactions","sub":{"2":{"id":"153000-s-4-15","title":"Moderate","mono":"<ul><li>Measles Virus Vaccine, Live (probable)<\/li><li>Mumps Virus Vaccine, Live (probable)<\/li><li>Rotavirus Vaccine, Live (probable)<\/li><li>Rubella Virus Vaccine, Live (probable)<\/li><li>Smallpox Vaccine (probable)<\/li><li>Typhoid Vaccine, Live (probable)<\/li><li>Varicella Virus Vaccine (probable)<\/li><\/ul>"}}},"5":{"id":"153000-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Diaphoresis, Flushing, Facial<\/li><li><b>Endocrine metabolic:<\/b>Shivering<\/li><li><b>Gastrointestinal:<\/b>Nausea, Vomiting<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Backache, Cramp<\/li><li><b>Respiratory:<\/b>Wheezing<\/li><li><b>Other:<\/b>Fever<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis (rare)<\/li><li><b>Neurologic:<\/b>Aseptic meningitis (Rare)<\/li><\/ul>"},"6":{"id":"153000-s-6","title":"Drug Name Info","sub":{"0":{"id":"153000-s-6-17","title":"US Trade Names","mono":"Cytogam<br\/>"},"2":{"id":"153000-s-6-19","title":"Class","mono":"Immune Serum<br\/>"},"3":{"id":"153000-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"153000-s-7","title":"Mechanism Of Action","mono":"Cytomegalovirus (CMV) immune globulin increases levels of antibody against CMV which reduces the incidence of serious CMV disease.<br\/>"},"9":{"id":"153000-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>do not shake or dilute<\/li><li>administer through a separate IV line or piggyback into a preexisting line of NS, D5W, D10W or other compatible solution, but should not be diluted to more than a 1 to 2 ratio<\/li><li>administer through a 15 micron in-line filter and a constant infusion pump; a smaller 0.2 micron in-line filter is also acceptable<\/li><li>begin infusion at 15 mg\/kg\/h and increase to 30 mg\/kg\/h, then 60 mg\/kg\/h as tolerated; infusion not to exceed 75 ml\/h<\/li><li>during the initial dose, rate increases may be made every 30 minutes as tolerated by the patient; subsequently, rate increases may be made every 15 minutes as tolerated<\/li><li>infusion should be completed within 12 hours of entering the vial<\/li><\/ul>"},"10":{"id":"153000-s-10","title":"Monitoring","mono":"<ul><li>vital signs<\/li><li>renal function, urine output<\/li><li>signs and symptoms of hemolysis<\/li><li>signs and symptoms of aseptic meningitis syndrome, especially with high dosing<\/li><li>signs and symptoms of non-cardiogenic pulmonary edema<\/li><\/ul>"},"13":{"id":"153000-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to defer vaccines for approximately 3 months after administration of cytomegalovirus immune globulin.<\/li><li>This product contains human albumin. Despite screening and testing, human plasma products carry a risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare professional.<\/li><li>This drug may cause diaphoresis, flushing, shivering, nausea, vomiting, arthralgia, back pain, cramps, or wheezing.<\/li><li>Instruct patient to report signs\/symptoms of decreased renal function, hemolysis, and non-cardiogenic pulmonary edema.<\/li><li>Advise patient to report signs\/symptoms of aseptic meningitis syndrome (fever, stiff neck, headache, malaise, photophobia, confusion), especially with high doses.<\/li><\/ul>"}}}